F 0761
Level of Harm - Minimal harm
or potential for actual harm
Residents Affected - Some
Ensure drugs and biologicals used in the facility are labeled in accordance with currently accepted
professional principles; and all drugs and biologicals must be stored in locked compartments, separately
locked, compartments for controlled drugs.
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** Based on
observation, interview, and record review, the facility failed to ensure the facility had safe guards in place for
their controlled drugs (a drug or other substance that is tightly controlled by the government because it may
be abused or cause addiction) to prevent loss of and/or diversion (the illegal distribution or abuse of
prescription drugs or their use for purposes not intended by the prescriber) of controlled drugs in the facility
for two of three sampled residents (Residents 1 and 2), by failing to:
1. Ensure Resident 1 ' s Oxycodone Hydrochloride [a narcotic (a drug that works in the brain to dull the
sense of pain) to relieve moderate to severe pain] 5 milligrams ([mg] a unit of measurement) was double
locked in the Director of Nursing ' s Office and/or medication cart (a moveable piece of equipment used in
healthcare facilities to store, transport, and dispense medicines, medical supplies, and emergency
equipment).
2. Ensure the medication refrigerator was locked containing Lorazepam (medication for treatment of
anxiety- schedule IV drug) was stored in the refrigerator per the facility ' s policy and procedure (P&P) titled
Storage of Medications.
These failures had the potential for theft, loss, drug diversion, and unauthorized consumption of
medications.
Findings:
a. During a review of Resident 1 ' s admission Record (Face Sheet), the Face Sheet indicated Resident 1
was admitted to the facility on [DATE] with diagnosis including of fibromyalgia (a chronic condition
characterized by widespread musculoskeletal pain, fatigue, and other symptoms).
During a review of Resident 1 ' s Nursing Progress Notes dated 1/15/2025, the Nursing Progress Notes
indicated Resident 1 was alert and oriented.
During a review of Resident 1 ' s Individual Resident ' s Narcotic Record dated 1/2025, the Individual
Resident ' s Narcotic Record indicated Resident 1 had two tablets (home medication brought in by Resident
1 upon admission to the facility) of Oxycodone 5 mg accounted for. The Resident ' s Individual Narcotic
Record indicated Resident 1 received one tablet of Oxycodone 5 mg on 1/15/2025 at 8:30 p.m.
b. During a review of Resident 2 ' s Face Sheet, the Face Sheet indicated Resident 2 was admitted
(continued on next page)
Any deficiency statement ending with an asterisk (*) denotes a deficiency which the institution may be excused from correcting providing it is determined that other
safeguards provide sufficient protection to the patients. (See instructions.) Except for nursing homes, the findings stated above are disclosable 90 days following the
date of survey whether or not a plan of correction is provided. For nursing homes, the above findings and plans of correction are disclosable 14 days following the date
these documents are made available to the facility. If deficiencies are cited, an approved plan of correction is requisite to continued program participation.
LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER
REPRESENTATIVE'S SIGNATURE
TITLE
(X6) DATE
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Facility ID:
If continuation sheet
Page 1 of 2
Event ID:
056425
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
056425
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
01/31/2025
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Studebaker Healthcare Center
13226 Studebaker Rd
Norwalk, CA 90650
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0761
Level of Harm - Minimal harm
or potential for actual harm
Residents Affected - Some
to the facility on [DATE] with diagnoses including of epilepsy (a brain disorder in which a person has
repeated seizures [uncontrolled movement]).
During a review of Resident 2 ' s Minimum Data Set (MDS – a federally mandated resident
assessment tool) dated 1/17/2025, the MDS indicated Resident 2 ' s cognition was severely impaired and
required substantial/maximal assistance (helper does more than half the effort) to complete Activities of
Daily Living (ADLs – routine tasks/activities such as bathing, dressing and toileting a person
performs daily).
During a review of Resident 2 ' s Physician Order dated 8/8/2024, the Physician Order indicated Lorazepam
solution 1 mg to be given intramuscularly ([IM] into a muscle) every six hours as needed for seizure
episode.
During a concurrent observation and interview on 1/31/2025 at 9:50 a.m. with the DON, in the station 2
medication room, Resident 1 ' s bottle of Oxycodone 5 mg was found in an unlocked drawer. The bottle of
Oxycodone 5 mg was observed containing 1 tablet. The medication refrigerator ' s padlock (a portable or
detachable lock) was observed lying on the top of the refrigerator. The DON stated the Resident 2 ' s
Lorazepam should be locked in the medication refrigerator.
During an interview on 1/31/2025 at 9:51 a.m. and subsequent interview at 1:45 p.m., the DON stated
facility staff reported to her that Resident 1 had a bottle of Oxycodone in her purse when she was admitted
and the bottle had two pills in the bottle. The DON stated the bottle of Oxycodone was stored in an
unlocked drawer in the Station 2 medication room. The DON stated the Lorazepam solution should be
locked in the refrigerator, and she could not provide an answer regarding what would happen to the
Lorazepam solution if not properly secured.
During a review of the facility ' s policy and procedure (P&P) titled Storage of Medications, dated 12/2023,
the P&P indicated controlled medications scheduled II, III, IV are designated as such by a red controlled
drug stamp and count sheet and are subject to special storage requirements. The P&P indicated the
controlled medications must be stored in a double locked storage compartment except when given as
regularly scheduled medications and part of the cycle medications (Schedule III and IV only). The P&P
indicated schedule II medications must be double locked.
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
056425
If continuation sheet
Page 2 of 2